MarginsXMarginsX
Home › Markets › Health Care › LXRX

Lexicon Pharmaceuticals Inc. (LXRX)

LXRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.75
-2.23% on the day
Market cap
$779.2M
Small cap
Revenue · 2025
$49.8M
+60.2% on 2024
Net income · 2025
-$50.3M
-101.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1062822/000106282226000050/0001062822-26-000050-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLXRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001062822
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$49.8M
Net income-$50.3M
Operating income-$48.9M
Net margin-101.1%
Operating margin-98.2%
Revenue growth+60.2%
Cash$34.3M
Total assets$185.0M
P/E (computed)Net income was not positive
P/S (computed)15.6×

Warning signs

Cash runway
10.7 months
$44.1M cash at September 30, 2026
Share count, 1 year
+22.5%
2025-11-04 to 2026-11-02 · +81.8% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$2.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$44.1M cash; operating cash flow -$12.3M a quarter.Report 2026-09-30
Shares outstanding445,234,571 (2026-11-02); 363,398,680 a year earlier; 244,924,695 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedownsLatest 2026-02-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Houston, Texas, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $2.7M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$11.3M-$14.0M-$8.1M$44.1M$51.9M$38.5M10-Q 2026-11-05
Q2 2026
2026-06-30
$692K-$31.8M-$9.2M$40.9M$51.4M$41.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$21.1M-$1.0M-$14.7M$38.1M$49.7M$69.6M10-Q 2026-05-07
Q4 2025
2025-12-31
$5.5M-$15.5M-$17.2M$34.3M$54.0M$49.8M10-K 2026-03-05
Q3 2025
2025-09-30
$14.2M-$12.8M-$23.8M$49.7M$56.5M$70.9M10-Q 2026-11-05
Q2 2025
2025-06-30
$28.9M$3.3M$17.0M$21.4M$56.1M$58.4M10-Q 2026-08-06
Q1 2025
2025-03-31
$1.3M-$25.3M-$43.8M$62.9M$100.7M$31.2M10-Q 2026-05-07
Q4 2024
2024-12-31
$26.6M-$33.8M-$21.5M$66.7M$100.3M$31.1M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-08-06
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxy
DEF 14A
DEFA14A2026-03-16

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.6%
1 month+11.2%
3 months-23.5%
Year to date+55.7%
1 year+24.3%
From 52-week high-32.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ORICOric Pharmaceuticals Inc.$7.52-4.33%$779.5M
IVAInventiva S.A. American Depository Shares$3.32-9.78%$784.5M
ARDXArdelyx Inc.$3.07-0.65%$771.7M
COLLCollegium Pharmaceutical Inc.$25.43+0.43%$790.2M
OBXObsidian Therapeutics Inc.$12.36-1.59%$763.5M
IRWDIronwood Pharmaceuticals Inc.$4.85+0.41%$802.9M
SNDXSyndax Pharmaceuticals Inc.$9.13-3.39%$821.6M
RIGLRigel Pharmaceuticals Inc.$43.73-1.64%$823.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier